Brainstorm Cell Therapeutics Inc. (BCLI)

Brainstorm Cell Therapeutics Inc. (BCLI) — VMCI valuation read

Brainstorm Cell Therapeutics Inc. sits at VMCI 37/100, with the Healthcare sector median at 50. That 13-point spread is the first thing to note on BCLI: it tells the reader the composite is unfavorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on BCLI are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on BCLI: BCLI trades at 22.0x earnings, 22% above the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 12.0% sits 2.0pp above the Healthcare median (10.0%). The Risk read: net debt to EBITDA of 2.7x is the rate-sensitivity line to watch, anchoring the bear scenario on a measurable balance-sheet metric.

BCLI fell 2.1% over the trailing 7 days, with a -19.9% read on a 30-day basis.